StockWatch: ALS Setback Hammers Amylyx, Longeveron Doubles on Positive Alzheimer’s Data

Amylyx shares lost roughly half their value in the past week, as investors reacted to FDA staffers recommending against approval of the company’s lead candidate. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee sided with agency staffers in recommending against approval by a 4–6 vote on Wednesday . . .

The post StockWatch: ALS Setback Hammers Amylyx, Longeveron Doubles on Positive Alzheimer’s Data appeared first on GEN – Genetic Engineering and Biotechnology News.

Source